Vol. 9 No. 2 (2013): March/April

Articles

• Ultralow dose fentanyl prevents development of chronic neuropathic pain in rats

  Elzbieta P. Wala, PhD, Joseph R. Holtman Jr, MD, PhD, Paul A. Sloan, MD

  85-96

  • Requires Subscription or Fee PDF (USD 56)

• Reported side effects, bother, satisfaction, and adherence in patients taking hydrocodone for non-cancer pain

  Kathryn P Anastassopoulos, MS, Wing Chow, PharmD, Crisanta I. Tapia, MHS, Rebecca Baik, BS, Bruce Moskowitz, MD, Myoung S. Kim, PhD

  97—109

  • Requires Subscription or Fee PDF (USD 56)

• Consumer attitudes about opioid addiction treatment: A focus group study in New York City

  Nancy L. Sohler, PhD, MPH, Linda Weiss, PhD, James E. Egan, MPH, Carolina M. López, BS, Jamie Favaro, LMSW, Robert Cordero, MSW, Chinazo O. Cunningham, MD, MS

  111-119

  • Requires Subscription or Fee PDF (USD 56)

• The use of urine drug monitoring in chronic opioid therapy: An analysis of current clinician behavior

  Zoe Clancy, PharmD, Katherine O’Connell, BS, Joseph Couto, PharmD, MBA

  121-127

  • Requires Subscription or Fee PDF (USD 56)

• Age, gender, and earlier opioid requirement associations with the rate of dose escalation in long-term opioid therapy

  Huijun Han, MD, PhD, Philip H. Kass, DVM, PhD, Barth L. Wilsey, MD, Chin-Shang Li, PhD

  129—138

  • Requires Subscription or Fee PDF (USD 56)

• A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: A descriptive analysis of six patients

  Beatrice Setnik, PhD, Carl L. Roland, PharmD, Veeraindar Goli, MD, Kenneth Sommerville, MD, Lynn Webster, MD

  139-150

  • Requires Subscription or Fee PDF (USD 56)